Koro CE, Bowlin SJ, Bourgeois N, et al.Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27:17-20.
2.
Peyrot M, Rubin RR, Lauritzin T, et al.Psychosocial problems and barriers to improved diabetes management: results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study. Diabet Med. 2005;22:1379-1385.
3.
UK Prospective Diabetes Study Group. UK prospective diabetes study 16: overview of 6 years’ therapy of type II diabetes—a progressive disease. Diabetes. 1995;44:1249-1258.
4.
Wright A, Burden AC, Paisey RB, et al.Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25:330-336.
5.
UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
6.
Polonsky WH, Fisher L, Guzman S, et al.Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28:2543-2545.
7.
Bohannon N. Insulin delivery using pen devices: simple-to-use tools may help young and old alike. Postgrad Med. 1999;106:57-58, 61-64, 68.
8.
Costa SD, Brackenridge B, Hicks D. A comparison of insulin pen use in the United States and the United Kingdom. Diabetes Educ. 2002;28:52-56, 59-60.
9.
Rubin RR, Peyrot M. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies. Diabetes Care. 2004;27:2495-2497.
10.
Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the diabetes control and complications trial. Am J Cardiol. 1995;75:894-903.
11.
Ohkubo Y, Kishikawa H. Araki E, et al.Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
12.
Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. JAMA. 2003;290:2159-2167.
13.
Nathan DM. Effects of intensive diabetes management on cardiovascular events in DCCT/EPIC: late breaking clinical trials. Paper presented at: Annual Meeting of the American Diabetes Association; June 2005; San Diego, Calif.
14.
Jain R, Allen E, Wahl T, et al.Efficacy of biphasic insulin aspart 70/30 in patients with T2DM not achieving glycemic targets on OADs with/without basal insulin therapy. Diabetes. 2005;54(suppl 1):A69.
15.
Raskin P, Allen E, Hollander P, et al, for the INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260-265.
16.
Riddle MC, Rosenstock J, Gerich JE. Insulin Glargine 4002 Study Investigators. The treat-to-target trial randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080-3086.
17.
Monnier L, Lapinski H, Collette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HBA(1c). Diabetes Care. 2003;26:881-885.
18.
DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of diagnostic criteria in Europe. Lancet. 1999;354:617-621.
19.
Malone JK, Kerr LF, Campaigne BN, et al.Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther. 2004;26:2034-2044.
20.
Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients’ fears and hopes about insulin therapy: the basis of patient reluctance. Diabetes Care. 1997;20:292-298.
21.
Diabetes Control and Complications Trial (DCCT) Research Group. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med. 1991;90:450-459.
22.
Fritsche A, Haring H-U, Togel E, et al.Treat-to-target with addon basal insulin: can insulin glargine reduce the barrier to target attainment? Paper presented at: Annual Meeting of the American Diabetes Association; June 2003; New Orleans, La.
23.
Boehm BO, Vaz JA, Brondsted L, et al.Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Intern Med. 2004;15:496-502.
24.
Hermansen K, Fontaine P, Kukolja KK, et al.Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia. 2004;47:622-629.
25.
Kilo C, Mezitis N, Jain R, et al.Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications. 2003;17:307-313.
26.
Vague P, Selam JL, Skeie S, et al.Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care. 2003;26:590-596.
27.
Miller CD, Phillips LS, Ziemer DC, et al.Clinical inertia. Ann Intern Med. 2001;135:825-834.
28.
Gabriely I, Shamoon H. Hypoglycemia in diabetes: common, often unrecognized. Cleve Clin J Med. 2004;71:335-342.
29.
Haak T, Tiengo A, Draeger E, et al.Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2005;7:56-64.
30.
Strowig SM, Aviles-Santa ML, Raskin P. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. Diabetes Care. 2002;25:1691-1698.
31.
Strowig SM, Aviles-Santa ML, Raskin P. Improved glycemic control without weight gain using triple therapy in type 2 diabetes. Diabetes Care. 2004;27:1577-1583.
32.
Nathan DM. Clinical practice: initial management of glycemia in type 2 diabetes mellitus. N Engl J Med. 2002;347:1342-1349.
33.
Rosenblum MS, Kane MP. Analysis of cost and utilization of health care services before and after initiation of insulin therapy in patients with type 2 diabetes mellitus. J Manag Care Pharm. 2003;9:309-316.
34.
Schwartz S, Sievers R, Strange P, et al.Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis. Diabetes Care. 2003;26:2238-2243.
